Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Alimentary Pharmacology & Therapeutics · 08.10.2026
DOI: 10.1111/apt.71020 ↗Kurz gefasst
Leserbrief in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 08.10.2026. Verfasst von Anastasios Koulaouzidis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, University of Southern Denmark (SDU), Odense, Denmark. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Research, University of Southern Denmark (SDU), Odense, Denmark.
- Department of Gastroenterology, Pomeranian Medical University in Szczecin (PUM), Szczecin, Poland.
- Endoklinika, the Center for Digestive Diseases, Szczecin, Poland.
ORCID-Profile: Anastasios Koulaouzidis, Wojciech Marlicz
Zitieren
APA
Koulaouzidis, A., & Marlicz, W. (2026). Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71020
Vancouver
Koulaouzidis A, Marlicz W. Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71020
BibTeX
@article{Koulaouzidis2026,
author = {Koulaouzidis, Anastasios and Marlicz, Wojciech},
title = {Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71020}
}
EUVIMED